XNYS 05 May, 2026 3:05 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 38.02 per share. | 02 Mar 2026 | 641 | 132,514 (0%) | 0% | 38.0 | 24,374 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 38.02 per share. | 02 Mar 2026 | 14,911 | 848,214 (2%) | 0% | 38.0 | 566,989 | Common Stock |
| Lance A. Berry | EVP, COO, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 38.02 per share. | 02 Mar 2026 | 5,178 | 176,269 (0%) | 0% | 38.0 | 196,893 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 38.02 per share. | 02 Mar 2026 | 2,183 | 170,105 (0%) | 0% | 38.0 | 83,008 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 38.02 per share. | 02 Mar 2026 | 2,784 | 206,522 (0%) | 0% | 38.0 | 105,861 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 02 Mar 2026 | 1,513 | 40,408 (0%) | 0% | 38.0 | 57,532 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 37.78 per share. | 02 Mar 2026 | 901 | 139,088 (0%) | 0% | 37.8 | 34,036 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 7,475 | 139,989 (0%) | 0% | 0 | Common Stock | |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 37.78 per share. | 02 Mar 2026 | 17,887 | 947,275 (2%) | 0% | 37.8 | 675,692 | Common Stock |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 116,948 | 965,162 (2%) | 0% | 0 | Common Stock | |
| Lance A. Berry | EVP, COO, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 40,874 | 217,143 (0%) | 0% | 0 | Common Stock | |
| Lance A. Berry | EVP, COO, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 37.78 per share. | 02 Mar 2026 | 6,316 | 210,827 (0%) | 0% | 37.8 | 238,591 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 38.00 per share. | 02 Mar 2026 | 8,962 | 185,095 (0%) | 0% | 38 | 340,556 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 27,795 | 197,900 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 37.78 per share. | 02 Mar 2026 | 3,843 | 194,057 (0%) | 0% | 37.8 | 145,172 | Common Stock |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 28,845 | 235,367 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 37.78 per share. | 02 Mar 2026 | 4,573 | 230,794 (0%) | 0% | 37.8 | 172,748 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 21,838 | 62,246 (0%) | 0% | 0 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | Sale of securities on an exchange or to another person at price $ 37.78 per share. | 02 Mar 2026 | 2,149 | 60,097 (0%) | 0% | 37.8 | 81,180 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2026 | 5,658 | 133,155 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.69 per share. | 23 Feb 2026 | 830 | 127,497 (0%) | 0% | 35.7 | 29,625 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 37.59 per share. | 23 Feb 2026 | 1,731 | 128,327 (0%) | 0% | 37.6 | 65,065 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 37.59 per share. | 23 Feb 2026 | 20,962 | 780,031 (1%) | 0% | 37.6 | 787,920 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 35.69 per share. | 23 Feb 2026 | 13,936 | 766,095 (1%) | 0% | 35.7 | 497,418 | Common Stock |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2026 | 97,030 | 863,125 (2%) | 0% | 0 | Common Stock | |
| Lance A. Berry | EVP, COO, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 37.59 per share. | 23 Feb 2026 | 4,981 | 148,450 (0%) | 0% | 37.6 | 187,226 | Common Stock |
| Lance A. Berry | EVP, COO, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 35.69 per share. | 23 Feb 2026 | 4,485 | 143,965 (0%) | 0% | 35.7 | 160,083 | Common Stock |
| Lance A. Berry | EVP, COO, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2026 | 37,482 | 181,447 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2026 | 20,085 | 172,288 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 37.59 per share. | 23 Feb 2026 | 3,079 | 153,871 (0%) | 0% | 37.6 | 115,733 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 35.69 per share. | 23 Feb 2026 | 1,668 | 152,203 (0%) | 0% | 35.7 | 59,536 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 37.59 per share. | 23 Feb 2026 | 3,773 | 190,943 (0%) | 0% | 37.6 | 141,820 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 35.69 per share. | 23 Feb 2026 | 2,075 | 188,868 (0%) | 0% | 35.7 | 74,063 | Common Stock |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2026 | 20,438 | 209,306 (0%) | 0% | 0 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2026 | 1,259 | 41,921 (0%) | 0% | 35.7 | 44,937 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2026 | 2,423 | 43,180 (0%) | 0% | 37.6 | 91,076 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 26.14 per share. | 31 Dec 2025 | 228 | 156,950 (0%) | 0% | 26.1 | 5,959 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 24.30 per share. | 31 Dec 2025 | 629 | 156,722 (0%) | 0% | 24.3 | 15,286 | Common Stock |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 24.30 per share. | 31 Dec 2025 | 874 | 194,716 (0%) | 0% | 24.3 | 21,240 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 31 Dec 2025 | 534 | 45,287 (0%) | 0% | 24.3 | 12,977 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 31 Dec 2025 | 316 | 45,603 (0%) | 0% | 26.1 | 8,260 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 45.11 per share. | 15 Dec 2025 | 5,000 | 193,842 (0%) | 0% | 45.1 | 225,550 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 44.42 per share. | 08 Dec 2025 | 4,572 | 130,058 (0%) | 0% | 44.4 | 203,084 | Common Stock |
| James Patrick Mackin | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 30,921 | 0 | - | - | Stock Options (Right to buy) | |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 45.46 per share. | 03 Dec 2025 | 30,921 | 800,993 (2%) | 0% | 45.5 | 1,405,700 | Common Stock |
| James Patrick Mackin | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.62 per share. | 03 Dec 2025 | 30,921 | 831,914 (2%) | 0% | 29.6 | 915,880 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 45.30 per share. | 03 Dec 2025 | 2,048 | 161,360 (0%) | 0% | 45.3 | 92,774 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 45.30 per share. | 03 Dec 2025 | 5,267 | 156,093 (0%) | 0% | 45.3 | 238,595 | Common Stock |
| James Patrick Mackin | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2025 | 30,921 | 0 | - | - | Stock Options (Right to buy) | |
| James Patrick Mackin | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.62 per share. | 02 Dec 2025 | 30,921 | 831,914 (2%) | 0% | 29.6 | 915,880 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 45.56 per share. | 02 Dec 2025 | 30,921 | 800,993 (2%) | 0% | 45.6 | 1,408,730 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Dec 2025 | 750 | 134,630 (0%) | 0% | 0 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 21 Nov 2025 | 20,301 | 65,054 (0%) | 0% | 18.4 | 374,350 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 21 Nov 2025 | 27,075 | 0 | - | - | Stock Options (Right to buy) | ||
| Marshall S. Stanton | SVP, Clinical & MD Affair | 21 Nov 2025 | 20,301 | 0 | - | - | Stock Options (Right to buy) | ||
| Marshall S. Stanton | SVP, Clinical & MD Affair | 21 Nov 2025 | 8,370 | 44,753 (0%) | 0% | 45.3 | 379,538 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 21 Nov 2025 | 18,705 | 53,123 (0%) | 0% | 44.9 | 840,042 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 21 Nov 2025 | 27,075 | 71,828 (0%) | 0% | 11.0 | 298,637 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 21 Nov 2025 | 5,715 | 44,753 (0%) | 0% | 45.3 | 259,152 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 21 Nov 2025 | 14,586 | 50,468 (0%) | 0% | 44.9 | 655,189 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 20 Nov 2025 | 2,033 | 20,301 | - | - | Stock Options (Right to buy) | ||
| Marshall S. Stanton | SVP, Clinical & MD Affair | 20 Nov 2025 | 1,355 | 44,753 (0%) | 0% | 44.3 | 59,997 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 20 Nov 2025 | 1,355 | 46,108 (0%) | 0% | 11.0 | 14,946 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 20 Nov 2025 | 2,033 | 44,753 (0%) | 0% | 44.3 | 90,092 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 20 Nov 2025 | 2,033 | 46,786 (0%) | 0% | 18.4 | 37,489 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 20 Nov 2025 | 11,888 | 44,753 (0%) | 0% | 44.1 | 524,736 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 20 Nov 2025 | 1,355 | 27,075 | - | - | Stock Options (Right to buy) | ||
| Elizabeth A. Hoff | Director | Sale of securities on an exchange or to another person at price $ 45.10 per share. | 18 Nov 2025 | 4,200 | 27,189 (0%) | 0% | 45.1 | 189,412 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 45.73 per share. | 17 Nov 2025 | 6,000 | 135,380 (0%) | 0% | 45.7 | 274,380 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2025 | 6,394 | 0 | - | - | Stock Options (Right to buy) | |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2025 | 6,393 | 0 | - | - | Stock Options (Right to buy) | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 45.17 per share. | 14 Nov 2025 | 6,394 | 163,408 (0%) | 0% | 45.2 | 288,817 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.62 per share. | 14 Nov 2025 | 6,394 | 169,802 (0%) | 0% | 29.6 | 189,390 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 14 Nov 2025 | 6,393 | 163,408 (0%) | 0% | 45 | 287,685 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.62 per share. | 14 Nov 2025 | 6,393 | 169,801 (0%) | 0% | 29.6 | 189,361 | Common Stock |
| John E. Davis | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2025 | 6,394 | 0 | - | - | Stock Options (Right to buy) | |
| John E. Davis | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2025 | 6,393 | 0 | - | - | Stock Options (Right to buy) | |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 45.17 per share. | 14 Nov 2025 | 6,394 | 198,842 (0%) | 0% | 45.2 | 288,817 | Common Stock |
| John E. Davis | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.62 per share. | 14 Nov 2025 | 6,394 | 205,236 (0%) | 0% | 29.6 | 189,390 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 44.67 per share. | 14 Nov 2025 | 6,393 | 198,842 (0%) | 0% | 44.7 | 285,575 | Common Stock |
| John E. Davis | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.62 per share. | 14 Nov 2025 | 6,393 | 205,235 (0%) | 0% | 29.6 | 189,361 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 45.86 per share. | 13 Nov 2025 | 3,482 | 141,380 (0%) | 0% | 45.9 | 159,678 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 45.86 per share. | 13 Nov 2025 | 34,210 | 800,993 (2%) | 0% | 45.9 | 1,568,802 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 45.86 per share. | 13 Nov 2025 | 5,761 | 163,408 (0%) | 0% | 45.9 | 264,188 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 45.86 per share. | 13 Nov 2025 | 6,563 | 198,842 (0%) | 0% | 45.9 | 300,966 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 13 Nov 2025 | 4,993 | 56,641 (0%) | 0% | 45.9 | 228,969 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 44.62 per share. | 10 Nov 2025 | 1,789 | 144,862 (0%) | 0% | 44.6 | 79,823 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 44.62 per share. | 10 Nov 2025 | 17,580 | 835,203 (2%) | 0% | 44.6 | 784,402 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 10,000 | 0 | - | - | Stock Options (Right to buy) | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 46.18 per share. | 10 Nov 2025 | 10,000 | 169,169 (0%) | 0% | 46.2 | 461,800 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.03 per share. | 10 Nov 2025 | 10,000 | 179,169 (0%) | 0% | 11.0 | 110,300 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 44.62 per share. | 10 Nov 2025 | 2,960 | 169,169 (0%) | 0% | 44.6 | 132,072 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 44.62 per share. | 10 Nov 2025 | 3,373 | 205,405 (0%) | 0% | 44.6 | 150,500 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 10 Nov 2025 | 2,566 | 61,634 (0%) | 0% | 44.6 | 114,492 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 27 Aug 2025 | 18,200 | 64,200 (0%) | 0% | 44.0 | 801,219 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 27 Aug 2025 | 18,200 | 82,400 (0%) | 0% | 11.0 | 200,746 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 27 Aug 2025 | 18,200 | 0 | - | - | Stock Option (Right to Buy) | ||
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 44.37 per share. | 25 Aug 2025 | 10,000 | 172,129 (0%) | 0% | 44.4 | 443,700 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.03 per share. | 25 Aug 2025 | 10,000 | 182,129 (0%) | 0% | 11.0 | 110,300 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 42.32 per share. | 15 Aug 2025 | 12,500 | 852,783 (2%) | 0% | 42.3 | 528,988 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 43.01 per share. | 12 Aug 2025 | 16,975 | 178,510 (0%) | 0% | 43.0 | 730,112 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 16,975 | 0 | - | - | Stock Option(Right to Buy) | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 43.02 per share. | 12 Aug 2025 | 6,381 | 172,129 (0%) | 0% | 43.0 | 274,498 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.24 per share. | 12 Aug 2025 | 16,975 | 195,485 (0%) | 0% | 26.2 | 445,424 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 43.67 per share. | 12 Aug 2025 | 10,802 | 208,778 (0%) | 0% | 43.7 | 471,756 | Common Stock |
| John E. Davis | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 10,802 | 0 | - | - | Stock Options (Right to buy) | |
| John E. Davis | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.24 per share. | 12 Aug 2025 | 10,802 | 219,580 (0%) | 0% | 26.2 | 283,444 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2025 | 7,992 | 0 | - | - | Stock Option (Right to Buy) | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 38.49 per share. | 08 Aug 2025 | 7,992 | 146,651 (0%) | 0% | 38.5 | 307,612 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.62 per share. | 08 Aug 2025 | 7,992 | 154,643 (0%) | 0% | 29.6 | 236,723 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 17 Jun 2025 | 13,764 | 65,436 (0%) | 0% | 29.5 | 406,038 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 17 Jun 2025 | 1,236 | 64,200 (0%) | 0% | 29.5 | 36,462 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 13 Jun 2025 | 1,826 | 79,200 (0%) | 0% | 28.4 | 51,909 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 13 Jun 2025 | 14,306 | 81,026 (0%) | 0% | 28.4 | 406,601 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 13 Jun 2025 | 1,253 | 95,332 (0%) | 0% | 28.5 | 35,669 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 13 Jun 2025 | 8,747 | 96,585 (0%) | 0% | 28.5 | 248,953 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 29.00 per share. | 27 May 2025 | 8,748 | 178,510 (0%) | 0% | 29 | 253,692 | Common Stock |
| Anthony B. Semedo | Director | Sale of securities on an exchange or to another person at price $ 28.47 per share. | 23 May 2025 | 2,600 | 33,059 (0%) | 0% | 28.5 | 74,027 | Common Stock |
| Anthony B. Semedo | Director | Sale of securities on an exchange or to another person at price $ 28.47 per share. | 23 May 2025 | 2,600 | 39,384 (0%) | 0% | 28.5 | 74,027 | Common Stock |
| Jeffrey H. Burbank | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 6,325 | 53,796 (0%) | 0% | 0 | Common Stock | |
| Jon W. Salveson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 6,325 | 129,840 (0%) | 0% | 0 | Common Stock | |
| Thomas F. Ackerman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 6,325 | 149,896 (0%) | 0% | 0 | Common Stock | |
| James W. Bullock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 6,325 | 68,647 (0%) | 0% | 0 | Common Stock | |
| Anthony B. Semedo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 6,325 | 41,984 (0%) | 0% | 0 | Common Stock | |
| Elizabeth A. Hoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 6,325 | 31,389 (0%) | 0% | 0 | Common Stock | |
| Daniel J. Bevevino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 6,325 | 150,061 (0%) | 0% | 0 | Common Stock | |
| Marna P. Borgstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 6,325 | 49,088 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 29.00 per share. | 21 May 2025 | 9,926 | 187,258 (0%) | 0% | 29 | 287,854 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 09 May 2025 | 4,811 | 105,332 (0%) | 0% | 29.1 | 140,145 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 09 May 2025 | 5,737 | 110,143 (0%) | 0% | 29.1 | 167,120 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 19,092 | 0 | - | - | Stock Options (Right to buy) | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 23.61 per share. | 11 Mar 2025 | 18,020 | 197,184 (0%) | 0% | 23.6 | 425,510 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.55 per share. | 11 Mar 2025 | 19,092 | 215,204 (0%) | 0% | 21.6 | 411,433 | Common Stock |
| John E. Davis | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.55 per share. | 11 Mar 2025 | 15,910 | 223,878 (0%) | 0% | 21.6 | 342,861 | Common Stock |
| John E. Davis | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 15,910 | 0 | - | - | Stock Options (Right to buy) | |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 23.61 per share. | 11 Mar 2025 | 15,100 | 208,778 (0%) | 0% | 23.6 | 356,549 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 10,261 | 147,699 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 24.80 per share. | 06 Mar 2025 | 1,048 | 146,651 (0%) | 0% | 24.8 | 25,995 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 24.76 per share. | 06 Mar 2025 | 70,700 | 865,283 (2%) | 0% | 24.8 | 1,750,843 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 24.80 per share. | 06 Mar 2025 | 17,739 | 860,368 (2%) | 0% | 24.8 | 440,005 | Common Stock |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 115,701 | 878,107 (2%) | 0% | 0 | Common Stock | |
| James Patrick Mackin | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.55 per share. | 06 Mar 2025 | 75,615 | 935,983 (2%) | 0% | 21.5 | 1,629,503 | Common Stock |
| James Patrick Mackin | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 75,615 | 0 | - | - | Stock Options (Right to buy) | |
| Lance A. Berry | Executive VP, CFO | Sale of securities on an exchange or to another person at price $ 24.80 per share. | 06 Mar 2025 | 4,909 | 153,431 (0%) | 0% | 24.8 | 121,764 | Common Stock |
| Lance A. Berry | Executive VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 48,100 | 158,340 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 25,493 | 198,236 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 24.80 per share. | 06 Mar 2025 | 2,124 | 196,112 (0%) | 0% | 24.8 | 52,685 | Common Stock |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 25,654 | 210,586 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 24.80 per share. | 06 Mar 2025 | 2,618 | 207,968 (0%) | 0% | 24.8 | 64,939 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 06 Mar 2025 | 1,603 | 115,880 (0%) | 0% | 24.8 | 39,761 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 06 Mar 2025 | 19,240 | 117,483 (0%) | 0% | 0 | Common Stock | ||
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 25.29 per share. | 05 Mar 2025 | 472 | 172,743 (0%) | 0% | 25.3 | 11,935 | Common Stock |
| Anthony B. Semedo | Director | Purchase of securities on an exchange or from another person at price $ 25.25 per share. | 05 Mar 2025 | 600 | 600 (0%) | 0% | 25.3 | 15,150 | Common Stock |
| Anthony B. Semedo | Director | Purchase of securities on an exchange or from another person at price $ 25.33 per share. | 05 Mar 2025 | 1,500 | 35,659 (0%) | 0% | 25.3 | 37,991 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 6,297 | 137,438 (0%) | 0% | 0 | Common Stock | |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 98,524 | 762,406 (1%) | 0% | 0 | Common Stock | |
| Lance A. Berry | Executive VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 34,435 | 110,240 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 23,416 | 173,215 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 24,301 | 184,932 (0%) | 0% | 0 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 28 Feb 2025 | 18,398 | 98,243 (0%) | 0% | 0 | Common Stock | ||
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 4,896 | 663,882 (1%) | 0% | 27.3 | 133,690 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 6,812 | 668,778 (1%) | 0% | 27.3 | 186,008 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 13,784 | 675,590 (1%) | 0% | 27.3 | 376,386 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 16,664 | 689,374 (1%) | 0% | 27.3 | 455,027 | Common Stock |
| Lance A. Berry | Executive VP, CFO | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 3,259 | 75,805 (0%) | 0% | 27.3 | 88,990 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 2,385 | 152,749 (0%) | 0% | 27.3 | 65,125 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 490 | 152,259 (0%) | 0% | 27.3 | 13,380 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 810 | 151,449 (0%) | 0% | 27.3 | 22,118 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 1,650 | 149,799 (0%) | 0% | 27.3 | 45,055 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 2,846 | 164,242 (0%) | 0% | 27.3 | 77,713 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 985 | 162,666 (0%) | 0% | 27.3 | 26,896 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 2,035 | 160,631 (0%) | 0% | 27.3 | 55,568 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 591 | 163,651 (0%) | 0% | 27.3 | 16,138 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 24 Feb 2025 | 2,299 | 82,233 (0%) | 0% | 27.3 | 62,776 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 24 Feb 2025 | 672 | 81,091 (0%) | 0% | 27.3 | 18,350 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 24 Feb 2025 | 470 | 81,763 (0%) | 0% | 27.3 | 12,834 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 24 Feb 2025 | 1,246 | 79,845 (0%) | 0% | 27.3 | 34,023 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 814 | 131,944 (0%) | 0% | 27.3 | 22,227 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 485 | 131,141 (0%) | 0% | 27.3 | 13,243 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 318 | 131,626 (0%) | 0% | 27.3 | 8,683 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 24 Feb 2025 | 1,706 | 132,758 (0%) | 0% | 27.3 | 46,584 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 15.20 per share. | 31 Dec 2024 | 977 | 154,839 (0%) | 0% | 15.2 | 14,850 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 21.63 per share. | 31 Dec 2024 | 295 | 155,134 (0%) | 0% | 21.6 | 6,381 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 31 Dec 2024 | 381 | 84,532 (0%) | 0% | 21.6 | 8,241 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 31 Dec 2024 | 855 | 84,151 (0%) | 0% | 15.2 | 12,996 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 15.20 per share. | 31 Dec 2024 | 1,398 | 167,088 (0%) | 0% | 15.2 | 21,250 | Common Stock |
| D. Horton Amy | VP, Chief Accounting Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2024 | 1,100 | 134,464 (0%) | 0% | 0 | Common Stock | |
| F. Jean Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 11 Dec 2024 | 4,035 | 153,862 (0%) | 0% | 30 | 121,050 | Common Stock |
| Holloway Jean F. | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 30.25 per share. | 11 Dec 2024 | 4,035 | 157,897 (0%) | 0% | 30.3 | 122,059 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 29.66 per share. | 06 Dec 2024 | 4,329 | 135,660 (0%) | 0% | 29.7 | 128,398 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 29.05 per share. | 06 Dec 2024 | 4,425 | 135,564 (0%) | 0% | 29.1 | 128,552 | Common Stock |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 04 Dec 2024 | 7,618 | 33,503 (0%) | 0% | 30 | 228,540 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 12,430 | 0 | - | - | Stock Option (Right to Buy) | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 26.18 per share. | 01 Oct 2024 | 12,430 | 139,989 (0%) | 0% | 26.2 | 325,415 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.55 per share. | 01 Oct 2024 | 12,430 | 152,419 (0%) | 0% | 21.6 | 267,867 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 26.55 per share. | 26 Aug 2024 | 3,167 | 161,932 (0%) | 0% | 26.6 | 84,096 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 25.31 per share. | 16 Aug 2024 | 6,858 | 36,678 (0%) | 0% | 25.3 | 173,586 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 25.31 per share. | 16 Aug 2024 | 2,562 | 34,116 (0%) | 0% | 25.3 | 64,848 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 25.76 per share. | 15 Aug 2024 | 2,383 | 165,099 (0%) | 0% | 25.8 | 61,393 | Common Stock |
| Anthony B. Semedo | Director | Sale of securities on an exchange or to another person at price $ 24.99 per share. | 13 Aug 2024 | 9,709 | 34,159 (0%) | 0% | 25.0 | 242,628 | Common Stock |
| Daniel J. Bevevino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 6,289 | 143,736 (0%) | 0% | 0 | Common Stock | |
| Jeffrey H. Burbank | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 6,289 | 47,471 (0%) | 0% | 0 | Common Stock | |
| Jon W. Salveson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 6,289 | 123,515 (0%) | 0% | 0 | Common Stock | |
| Thomas F. Ackerman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 6,289 | 143,571 (0%) | 0% | 0 | Common Stock | |
| James W. Bullock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 6,289 | 62,322 (0%) | 0% | 0 | Common Stock | |
| Marna P. Borgstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 6,289 | 42,763 (0%) | 0% | 0 | Common Stock | |
| Anthony B. Semedo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 6,289 | 43,868 (0%) | 0% | 0 | Common Stock | |
| Elizabeth A. Hoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 6,289 | 25,064 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 23.42 per share. | 10 May 2024 | 1,250 | 167,482 (0%) | 0% | 23.4 | 29,275 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 23.79 per share. | 09 May 2024 | 979 | 168,732 (0%) | 0% | 23.8 | 23,286 | Common Stock |
| Marshall Stanton S. | SVP, Clinical & MD Affair | 20 Mar 2024 | 2,183 | 83,296 (0%) | 0% | 20.4 | 44,511 | Common Stock | |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 15 Mar 2024 | 1,462 | 41,121 (0%) | 0% | 20 | 29,240 | Common Stock |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 14 Mar 2024 | 3,994 | 42,583 (0%) | 0% | 20 | 79,880 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 19.94 per share. | 12 Mar 2024 | 5,000 | 43,536 (0%) | 0% | 19.9 | 99,720 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,578 | 141,109 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 1,152 | 139,957 (0%) | 0% | 18.7 | 21,568 | Common Stock |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 28,618 | 719,558 (1%) | 0% | 0 | Common Stock | |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 13,996 | 705,562 (1%) | 0% | 18.7 | 262,037 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 2,380 | 169,669 (0%) | 0% | 18.7 | 44,559 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 5,724 | 172,049 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 5,724 | 167,659 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 2,022 | 165,637 (0%) | 0% | 18.7 | 37,856 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 1,157 | 48,503 (0%) | 0% | 18.7 | 21,661 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,578 | 49,660 (0%) | 0% | 0 | Common Stock | |
| Rochelle L. Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 1,157 | 46,536 (0%) | 0% | 18.7 | 21,662 | Common Stock |
| Rochelle L. Maney | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,578 | 47,693 (0%) | 0% | 0 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 1,506 | 85,438 (0%) | 0% | 18.7 | 28,195 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 5,724 | 86,944 (0%) | 0% | 0 | Common Stock | |
| Andrew M. Green | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,578 | 47,701 (0%) | 0% | 0 | Common Stock | |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 1,160 | 46,541 (0%) | 0% | 18.7 | 21,718 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,578 | 141,141 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 1,152 | 139,989 (0%) | 0% | 18.7 | 21,568 | Common Stock |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 28,618 | 720,034 (1%) | 0% | 0 | Common Stock | |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 13,996 | 706,038 (1%) | 0% | 18.7 | 262,037 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 2,380 | 169,711 (0%) | 0% | 18.7 | 44,559 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 5,724 | 172,091 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 5,724 | 167,712 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 2,022 | 165,690 (0%) | 0% | 18.7 | 37,856 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,578 | 49,693 (0%) | 0% | 0 | Common Stock | |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 1,157 | 48,536 (0%) | 0% | 18.7 | 21,661 | Common Stock |
| Rochelle L. Maney | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,578 | 47,726 (0%) | 0% | 0 | Common Stock | |
| Rochelle L. Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 1,157 | 46,569 (0%) | 0% | 18.7 | 21,662 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 01 Mar 2024 | 1,506 | 85,479 (0%) | 0% | 18.7 | 28,195 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 01 Mar 2024 | 5,724 | 86,985 (0%) | 0% | 0 | Common Stock | ||
| Andrew M. Green | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,578 | 47,737 (0%) | 0% | 0 | Common Stock | |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 01 Mar 2024 | 1,160 | 46,577 (0%) | 0% | 18.7 | 21,718 | Common Stock |
| Patrick Mackin James | President & CEO | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 4,837 | 690,940 (1%) | 0% | 19.8 | 95,939 | Common Stock |
| Green Andrew M. | VP Regulatory | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 421 | 44,123 (0%) | 0% | 19.8 | 8,350 | Common Stock |
| Florian Tyrs | VP, Global Operations | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 339 | 21,558 (0%) | 0% | 19.8 | 6,724 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 19.84 per share. | 27 Feb 2024 | 485 | 166,325 (0%) | 0% | 19.8 | 9,620 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 325 | 137,531 (0%) | 0% | 19.8 | 6,446 | Common Stock |
| E. Davis John | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 584 | 161,935 (0%) | 0% | 19.8 | 11,583 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 325 | 137,563 (0%) | 0% | 19.8 | 6,446 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 4,837 | 691,416 (1%) | 0% | 19.8 | 95,939 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 19.84 per share. | 27 Feb 2024 | 485 | 166,367 (0%) | 0% | 19.8 | 9,620 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 584 | 161,988 (0%) | 0% | 19.8 | 11,583 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 325 | 46,115 (0%) | 0% | 19.8 | 6,446 | Common Stock |
| Rochelle L. Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 19.84 per share. | 27 Feb 2024 | 370 | 44,148 (0%) | 0% | 19.8 | 7,339 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 27 Feb 2024 | 465 | 81,261 (0%) | 0% | 19.8 | 9,223 | Common Stock | |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 421 | 44,159 (0%) | 0% | 19.8 | 8,350 | Common Stock |
| Rochelle Maney L. | VP, Quality | Sale of securities on an exchange or to another person at price $ 19.84 per share. | 27 Feb 2024 | 370 | 44,115 (0%) | 0% | 19.8 | 7,339 | Common Stock |
| Matthew Getz A. | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 325 | 46,082 (0%) | 0% | 19.8 | 6,446 | Common Stock |
| S. Marshall Stanton | SVP, Clinical & MD Affair | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 27 Feb 2024 | 465 | 81,220 (0%) | 0% | 19.8 | 9,223 | Common Stock |
| Tyrs Florian | VP, Global Operations | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 26 Feb 2024 | 893 | 21,897 (0%) | 0% | 20.3 | 18,103 | Common Stock |
| S. Marshall Stanton | SVP, Clinical & MD Affair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 5,386 | 74,089 (0%) | 0% | 0 | Common Stock | |
| M. Andrew Green | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 11,100 | 36,667 (0%) | 0% | 0 | Common Stock | |
| A. Matthew Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,185 | 40,123 (0%) | 0% | 20.3 | 24,021 | Common Stock |
| Patrick James Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 40,404 | 668,441 (1%) | 0% | 0 | Common Stock | |
| Davis John E. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,904 | 162,519 (0%) | 0% | 20.3 | 38,596 | Common Stock |
| James Mackin Patrick | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 58,648 | 708,945 (1%) | 0% | 0 | Common Stock | |
| Getz Matthew A. | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,128 | 46,407 (0%) | 0% | 20.3 | 22,866 | Common Stock |
| E. Davis John | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 12,736 | 164,423 (0%) | 0% | 0 | Common Stock | |
| M. Andrew Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,185 | 38,848 (0%) | 0% | 20.3 | 24,021 | Common Stock |
| L. Maney Rochelle | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 7,893 | 37,016 (0%) | 0% | 0 | Common Stock | |
| L. Rochelle Maney | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,366 | 40,382 (0%) | 0% | 0 | Common Stock | |
| Mackin James Patrick | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 89,001 | 628,037 (1%) | 0% | 0 | Common Stock | |
| Mackin Patrick James | President & CEO | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 13,168 | 695,777 (1%) | 0% | 20.3 | 266,930 | Common Stock |
| Andrew M. Green | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 6,914 | 45,762 (0%) | 0% | 0 | Common Stock | |
| Marshall Stanton S. | SVP, Clinical & MD Affair | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,448 | 81,685 (0%) | 0% | 20.3 | 29,353 | Common Stock |
| E. John Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,610 | 151,687 (0%) | 0% | 20.3 | 32,636 | Common Stock |
| D. Amy Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,366 | 133,604 (0%) | 0% | 0 | Common Stock | |
| L. Rochelle Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,130 | 44,485 (0%) | 0% | 20.3 | 22,906 | Common Stock |
| Jean Holloway F. | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 12,836 | 168,376 (0%) | 0% | 0 | Common Stock | |
| Rochelle L. Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,185 | 39,197 (0%) | 0% | 20.3 | 24,021 | Common Stock |
| Maney Rochelle L. | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 6,418 | 45,615 (0%) | 0% | 0 | Common Stock | |
| John Davis E. | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 19,734 | 147,911 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 6,418 | 138,854 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,366 | 133,604 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 966 | 137,888 (0%) | 0% | 20.3 | 19,582 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,168 | 132,436 (0%) | 0% | 20.3 | 23,677 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 12,968 | 696,253 (1%) | 0% | 20.3 | 262,876 | Common Stock |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 58,648 | 709,221 (1%) | 0% | 0 | Common Stock | |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 17,868 | 650,573 (1%) | 0% | 20.3 | 362,204 | Common Stock |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 40,404 | 668,441 (1%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,543 | 166,852 (0%) | 0% | 20.3 | 31,278 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 12,836 | 168,395 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,295 | 155,559 (0%) | 0% | 20.3 | 26,251 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 5,386 | 156,854 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,875 | 162,572 (0%) | 0% | 20.3 | 38,008 | Common Stock |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 12,736 | 164,447 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,586 | 151,711 (0%) | 0% | 20.3 | 32,150 | Common Stock |
| John E. Davis | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 5,386 | 153,279 (0%) | 0% | 0 | Common Stock | |
| Matthew A. Getz | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 7,412 | 47,552 (0%) | 0% | 0 | Common Stock | |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,112 | 46,440 (0%) | 0% | 20.3 | 22,541 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,366 | 41,308 (0%) | 0% | 0 | Common Stock | |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,168 | 40,140 (0%) | 0% | 20.3 | 23,677 | Common Stock |
| Rochelle L. Maney | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,366 | 40,382 (0%) | 0% | 0 | Common Stock | |
| Rochelle L. Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,168 | 39,214 (0%) | 0% | 20.3 | 23,677 | Common Stock |
| Rochelle L. Maney | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 6,418 | 45,632 (0%) | 0% | 0 | Common Stock | |
| Rochelle L. Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,114 | 44,518 (0%) | 0% | 20.3 | 22,582 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2024 | 10,644 | 83,157 (0%) | 0% | 0 | Common Stock | ||
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2024 | 1,431 | 81,726 (0%) | 0% | 20.3 | 29,008 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2024 | 5,386 | 74,089 (0%) | 0% | 0 | Common Stock | ||
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2024 | 1,576 | 72,513 (0%) | 0% | 20.3 | 31,947 | Common Stock | |
| Andrew M. Green | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,366 | 40,033 (0%) | 0% | 0 | Common Stock | |
| Andrew M. Green | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 6,914 | 45,779 (0%) | 0% | 0 | Common Stock | |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,168 | 38,865 (0%) | 0% | 20.3 | 23,677 | Common Stock |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,199 | 44,580 (0%) | 0% | 20.3 | 24,305 | Common Stock |
| M. Green Andrew | VP Regulatory | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,218 | 44,544 (0%) | 0% | 20.3 | 24,690 | Common Stock |
| D. Horton Amy | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 980 | 137,856 (0%) | 0% | 20.3 | 19,866 | Common Stock |
| Holloway Jean F. | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,566 | 166,810 (0%) | 0% | 20.3 | 31,745 | Common Stock |
| Stanton S. Marshall | SVP, Clinical & MD Affair | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,600 | 72,489 (0%) | 0% | 20.3 | 32,434 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 9,250 | 37,942 (0%) | 0% | 0 | Common Stock | |
| F. Holloway Jean | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,314 | 155,540 (0%) | 0% | 20.3 | 26,636 | Common Stock |
| A. Matthew Getz | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,366 | 41,308 (0%) | 0% | 0 | Common Stock | |
| E. Davis John | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 5,386 | 153,297 (0%) | 0% | 0 | Common Stock | |
| Getz Matthew A. | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 7,412 | 47,535 (0%) | 0% | 0 | Common Stock | |
| C. Thomson Robert | VP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 8,165 | 13,291 (0%) | 0% | 0 | Common Stock | |
| Mackin Patrick James | President & CEO | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 18,144 | 650,297 (1%) | 0% | 20.3 | 367,799 | Common Stock |
| Lance Berry A. | Executive VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 37,000 | 79,064 (0%) | 0% | 0 | Common Stock | |
| Green Andrew M. | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,366 | 40,033 (0%) | 0% | 0 | Common Stock | |
| Horton D. Amy | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 7,893 | 130,238 (0%) | 0% | 0 | Common Stock | |
| Holloway Jean F. | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 19,610 | 151,468 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 6,418 | 138,836 (0%) | 0% | 0 | Common Stock | |
| S. Stanton Marshall | SVP, Clinical & MD Affair | 23 Feb 2024 | 14,800 | 68,703 (0%) | 0% | 0 | Common Stock | ||
| Stanton Marshall S. | SVP, Clinical & MD Affair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 10,644 | 83,133 (0%) | 0% | 0 | Common Stock | |
| Amy Horton D. | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.27 per share. | 23 Feb 2024 | 1,186 | 132,418 (0%) | 0% | 20.3 | 24,042 | Common Stock |
| Jean Holloway F. | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 5,386 | 156,854 (0%) | 0% | 0 | Common Stock | |
| Tyrs Florian | VP, Global Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 6,537 | 22,790 (0%) | 0% | 0 | Common Stock | |
| Amy Horton D. | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 18.87 per share. | 20 Feb 2024 | 1,329 | 122,711 (0%) | 0% | 18.9 | 25,072 | Common Stock |
| Horton D. Amy | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 18.87 per share. | 20 Feb 2024 | 366 | 122,345 (0%) | 0% | 18.9 | 6,905 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 18.86 per share. | 20 Feb 2024 | 1,192 | 131,858 (0%) | 0% | 18.9 | 22,487 | Common Stock |
| Rochelle Maney L. | VP, Quality | Sale of securities on an exchange or to another person at price $ 18.86 per share. | 20 Feb 2024 | 407 | 29,123 (0%) | 0% | 18.9 | 7,678 | Common Stock |
| James Mackin Patrick | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 59,225 | 0 | - | - | Stock Option(Right to Buy) | |
| A. Matthew Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 18.87 per share. | 20 Feb 2024 | 366 | 28,692 (0%) | 0% | 18.9 | 6,905 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 18.87 per share. | 20 Feb 2024 | 1,329 | 29,058 (0%) | 0% | 18.9 | 25,072 | Common Stock |
| John E. Davis | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.87 per share. | 20 Feb 2024 | 2,060 | 128,673 (0%) | 0% | 18.9 | 38,862 | Common Stock |
| Mackin James Patrick | President & CEO | Sale of securities on an exchange or to another person at price $ 18.85 per share. | 20 Feb 2024 | 59,225 | 551,880 (1%) | 0% | 18.9 | 1,116,516 | Common Stock |
| F. Jean Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 18.86 per share. | 20 Feb 2024 | 1,871 | 133,514 (0%) | 0% | 18.9 | 35,296 | Common Stock |
| Patrick James Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 18.86 per share. | 20 Feb 2024 | 10,088 | 541,792 (1%) | 0% | 18.9 | 190,310 | Common Stock |
| Jean Holloway F. | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 18.86 per share. | 20 Feb 2024 | 464 | 133,050 (0%) | 0% | 18.9 | 8,753 | Common Stock |
| Florian Tyrs | VP, Global Operations | Sale of securities on an exchange or to another person at price $ 18.86 per share. | 20 Feb 2024 | 249 | 16,253 (0%) | 0% | 18.9 | 4,697 | Common Stock |
| Mackin Patrick James | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.30 per share. | 20 Feb 2024 | 59,225 | 611,105 (1%) | 0% | 16.3 | 965,368 | Common Stock |
| Davis E. John | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.86 per share. | 20 Feb 2024 | 496 | 128,177 (0%) | 0% | 18.9 | 9,357 | Common Stock |
| Mackin Patrick James | President & CEO | Sale of securities on an exchange or to another person at price $ 18.87 per share. | 20 Feb 2024 | 2,756 | 539,036 (1%) | 0% | 18.9 | 51,992 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.30 per share. | 02 Jan 2024 | 21,229 | 154,749 (0%) | 0% | 16.3 | 346,033 | Common Stock |
| Holloway F. Jean | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 21,229 | 0 | - | - | Stock Option (Right to Buy) | |
| Davis John E. | Senior VP, Global Sales | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 13,562 | 0 | - | - | Stock Option (Right to Buy) | |
| John E. Davis | Senior VP, Global Sales | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.30 per share. | 02 Jan 2024 | 13,562 | 142,295 (0%) | 0% | 16.3 | 221,061 | Common Stock |
| Jean Holloway F. | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 02 Jan 2024 | 21,229 | 133,520 (0%) | 0% | 18 | 382,122 | Common Stock |
| Davis John E. | Senior VP, Global Sales | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 02 Jan 2024 | 13,562 | 128,733 (0%) | 0% | 18 | 244,116 | Common Stock |
| Jean Holloway F. | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 10.30 per share. | 31 Dec 2023 | 1,393 | 134,913 (0%) | 0% | 10.3 | 14,351 | Common Stock |
| Stanton S. Marshall | SVP, Clinical & MD Affair | 31 Dec 2023 | 565 | 53,903 (0%) | 0% | 14.6 | 8,255 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 14.61 per share. | 31 Dec 2023 | 472 | 135,385 (0%) | 0% | 14.6 | 6,897 | Common Stock |
| S. Marshall Stanton | SVP, Clinical & MD Affair | 31 Dec 2023 | 1,261 | 53,338 (0%) | 0% | 10.3 | 12,991 | Common Stock | |
| E. Davis John | Senior VP, Global Sales | Grant, award, or other acquisition of securities at price $ 10.30 per share. | 31 Dec 2023 | 2,000 | 130,733 (0%) | 0% | 10.3 | 20,604 | Common Stock |
| D. Amy Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 15 Dec 2023 | 14,397 | 124,040 (0%) | 0% | 19 | 273,543 | Common Stock |
| D. Horton Amy | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.30 per share. | 15 Dec 2023 | 14,397 | 138,437 (0%) | 0% | 16.3 | 234,671 | Common Stock |
| D. Horton Amy | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 14,397 | 0 | - | - | Stock Option (Right to Buy) | |
| A. Lance Berry | Executive VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 93,633 | 93,633 | - | - | Stock Option (Right to Buy) | |
| A. Lance Berry | Executive VP, CFO | Grant, award, or other acquisition of securities at price $ 17.83 per share. | 06 Dec 2023 | 42,064 | 42,064 (0%) | 0% | 17.8 | 750,001 | Common Stock |
| D. Amy Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 17.83 per share. | 06 Dec 2023 | 20,191 | 124,040 (0%) | 0% | 17.8 | 360,006 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Gift of securities by or to the insider at price $ 17.51 per share. | 27 Nov 2023 | 1,750 | 103,849 (0%) | 0% | 17.5 | 30,643 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 17.34 per share. | 27 Nov 2023 | 2,101 | 105,599 (0%) | 0% | 17.3 | 36,431 | Common Stock |
| Florian Tyrs | VP, Global Operations | Grant, award, or other acquisition of securities at price $ 16.79 per share. | 08 Aug 2023 | 2,107 | 16,502 (0%) | 0% | 16.8 | 35,377 | Common Stock |
| Florian Tyrs | VP, Global Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2023 | 4,699 | 4,699 | - | - | Stock Option (Right to Buy) | |
| Robert C. Thomson | VP Research & Development | Grant, award, or other acquisition of securities at price $ 15.49 per share. | 09 Jun 2023 | 5,126 | 5,126 (0%) | 0% | 15.5 | 79,402 | Common Stock |
| Robert C. Thomson | VP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 11,490 | 11,490 | - | - | Common Stock | |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 15.88 per share. | 07 Jun 2023 | 6,329 | 30,387 (0%) | 0% | 15.9 | 100,483 | Common Stock |
| Daniel J. Bevevino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,709 | 137,447 (0%) | 0% | 0 | Common Stock | |
| Jeffrey H. Burbank | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,709 | 41,182 (0%) | 0% | 0 | Common Stock | |
| Jon W. Salveson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,709 | 117,226 (0%) | 0% | 0 | Common Stock | |
| Thomas F. Ackerman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,709 | 137,282 (0%) | 0% | 0 | Common Stock | |
| James W. Bullock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,709 | 56,033 (0%) | 0% | 0 | Common Stock | |
| Marna P. Borgstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,709 | 36,474 (0%) | 0% | 0 | Common Stock | |
| Dennis B Maier | SVP, Operations | Sale of securities on an exchange or to another person at price $ 15.27 per share. | 06 Jun 2023 | 15,876 | 35,102 (0%) | 0% | 15.3 | 242,363 | Common Stock |
| Dennis B Maier | SVP, Operations | Sale of securities on an exchange or to another person at price $ 15.34 per share. | 06 Jun 2023 | 378 | 34,724 (0%) | 0% | 15.3 | 5,800 | Common Stock |
| Anthony B. Semedo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,709 | 37,579 (0%) | 0% | 0 | Common Stock | |
| Elizabeth A. Hoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,709 | 18,775 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,290 | 108,402 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 01 Mar 2023 | 702 | 107,700 (0%) | 0% | 13.4 | 9,415 | Common Stock |
| David Ashley Lee | Executive VP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 4,579 | 348,618 (0%) | 0% | 0 | Common Stock | |
| David Ashley Lee | Executive VP, COO & CFO | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 01 Mar 2023 | 1,401 | 347,217 (0%) | 0% | 13.4 | 18,790 | Common Stock |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 01 Mar 2023 | 9,990 | 551,880 (1%) | 0% | 13.4 | 133,984 | Common Stock |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 21,818 | 561,870 (1%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 3,663 | 134,427 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 01 Mar 2023 | 907 | 133,520 (0%) | 0% | 13.4 | 12,165 | Common Stock |
| John E. Davis | Senior VP, Global Sales | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 01 Mar 2023 | 1,121 | 128,733 (0%) | 0% | 13.4 | 15,035 | Common Stock |
| John E. Davis | Senior VP, Global Sales | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 3,663 | 129,854 (0%) | 0% | 0 | Common Stock | |
| Dennis B Maier | SVP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 3,663 | 52,099 (0%) | 0% | 0 | Common Stock | |
| Dennis B Maier | SVP, Operations | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 01 Mar 2023 | 1,121 | 50,978 (0%) | 0% | 13.4 | 15,035 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 01 Mar 2023 | 702 | 36,716 (0%) | 0% | 13.4 | 9,415 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,290 | 37,418 (0%) | 0% | 0 | Common Stock | |
| Rochelle L. Maney | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,290 | 30,351 (0%) | 0% | 0 | Common Stock | |
| Rochelle L. Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 01 Mar 2023 | 821 | 29,530 (0%) | 0% | 13.4 | 11,011 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 01 Mar 2023 | 907 | 52,077 (0%) | 0% | 13.4 | 12,165 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 01 Mar 2023 | 3,663 | 52,984 (0%) | 0% | 0 | Common Stock | ||
| Andrew M. Green | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,290 | 26,392 (0%) | 0% | 0 | Common Stock | |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 01 Mar 2023 | 825 | 25,567 (0%) | 0% | 13.4 | 11,065 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 747 | 102,544 (0%) | 0% | 12.9 | 9,665 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 672 | 106,112 (0%) | 0% | 12.9 | 8,694 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 2,356 | 103,291 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 4,240 | 106,784 (0%) | 0% | 0 | Common Stock | |
| David Ashley Lee | Executive VP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 10,122 | 345,641 (0%) | 0% | 0 | Common Stock | |
| David Ashley Lee | Executive VP, COO & CFO | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 1,602 | 344,039 (0%) | 0% | 12.9 | 20,727 | Common Stock |
| David Ashley Lee | Executive VP, COO & CFO | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 1,492 | 335,519 (0%) | 0% | 12.9 | 19,303 | Common Stock |
| David Ashley Lee | Executive VP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 4,713 | 337,011 (0%) | 0% | 0 | Common Stock | |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 42,148 | 550,037 (1%) | 0% | 0 | Common Stock | |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 9,985 | 540,052 (1%) | 0% | 12.9 | 129,186 | Common Stock |
| James Patrick Mackin | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 28,282 | 520,534 (1%) | 0% | 0 | Common Stock | |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 12,645 | 507,889 (1%) | 0% | 12.9 | 163,601 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 994 | 130,764 (0%) | 0% | 12.9 | 12,860 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 966 | 124,002 (0%) | 0% | 12.9 | 12,498 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 3,770 | 124,968 (0%) | 0% | 0 | Common Stock | |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 7,756 | 131,758 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Senior VP, Global Sales | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 7,630 | 127,399 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Senior VP, Global Sales | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 1,208 | 126,191 (0%) | 0% | 12.9 | 15,629 | Common Stock |
| John E. Davis | Senior VP, Global Sales | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 3,770 | 120,954 (0%) | 0% | 0 | Common Stock | |
| John E. Davis | Senior VP, Global Sales | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 1,185 | 119,769 (0%) | 0% | 12.9 | 15,332 | Common Stock |
| Dennis B Maier | SVP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 6,318 | 49,418 (0%) | 0% | 0 | Common Stock | |
| Dennis B Maier | SVP, Operations | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 982 | 48,436 (0%) | 0% | 12.9 | 12,705 | Common Stock |
| Dennis B Maier | SVP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 3,770 | 44,448 (0%) | 0% | 0 | Common Stock | |
| Dennis B Maier | SVP, Operations | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 1,348 | 43,100 (0%) | 0% | 12.9 | 17,440 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 4,240 | 35,850 (0%) | 0% | 0 | Common Stock | |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 722 | 35,128 (0%) | 0% | 12.9 | 9,341 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 2,356 | 32,488 (0%) | 0% | 0 | Common Stock | |
| Matthew A. Getz | VP, Human Resources | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 878 | 31,610 (0%) | 0% | 12.9 | 11,360 | Common Stock |
| Rochelle L. Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 878 | 25,017 (0%) | 0% | 12.9 | 11,360 | Common Stock |
| Rochelle L. Maney | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 2,356 | 25,895 (0%) | 0% | 0 | Common Stock | |
| Rochelle L. Maney | VP, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 4,240 | 29,257 (0%) | 0% | 0 | Common Stock | |
| Rochelle L. Maney | VP, Quality | Grant, award, or other acquisition of securities at price $ 12.94 per share. | 23 Feb 2023 | 790 | 28,467 (0%) | 0% | 12.9 | 10,221 | Common Stock |
| Rochelle L. Maney | VP, Quality | Sale of securities on an exchange or to another person at price $ 13.24 per share. | 23 Feb 2023 | 406 | 28,061 (0%) | 0% | 13.2 | 5,374 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2023 | 3,770 | 44,218 (0%) | 0% | 0 | Common Stock | ||
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2023 | 1,161 | 49,321 (0%) | 0% | 12.9 | 15,021 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2023 | 7,440 | 50,482 (0%) | 0% | 0 | Common Stock | ||
| Marshall S. Stanton | SVP, Clinical & MD Affair | 23 Feb 2023 | 1,176 | 43,042 (0%) | 0% | 12.9 | 15,215 | Common Stock | |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 869 | 24,102 (0%) | 0% | 12.9 | 11,243 | Common Stock |
| Andrew M. Green | VP Regulatory | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 23 Feb 2023 | 878 | 20,309 (0%) | 0% | 12.9 | 11,360 | Common Stock |
| Andrew M. Green | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 4,662 | 24,971 (0%) | 0% | 0 | Common Stock | |
| Andrew M. Green | VP Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 2,356 | 21,187 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 258 | 100,935 (0%) | 0% | 14.0 | 3,602 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 17,713 | 0 | - | - | Stock Options (Right to buy) | |
| Amy D. Horton | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 3,000 | 0 | - | - | Stock Options (Right to buy) | |
| Amy D. Horton | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.24 per share. | 17 Feb 2023 | 17,713 | 117,663 (0%) | 0% | 10.2 | 181,381 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 14.08 per share. | 17 Feb 2023 | 15,000 | 102,663 (0%) | 0% | 14.1 | 211,161 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.24 per share. | 17 Feb 2023 | 3,000 | 105,663 (0%) | 0% | 10.2 | 30,720 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 14.13 per share. | 17 Feb 2023 | 3,000 | 102,663 (0%) | 0% | 14.1 | 42,392 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 363 | 102,300 (0%) | 0% | 14.0 | 5,067 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 1,107 | 101,193 (0%) | 0% | 14.0 | 15,454 | Common Stock |
| David Ashley Lee | Executive VP, COO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 526 | 332,298 (0%) | 0% | 14.0 | 7,343 | Common Stock |
| David Ashley Lee | Executive VP, COO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 2,104 | 332,824 (0%) | 0% | 14.0 | 29,372 | Common Stock |
| David Ashley Lee | Executive VP, COO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 635 | 334,928 (0%) | 0% | 14.0 | 8,865 | Common Stock |
| James Patrick Mackin | President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 2,139 | 492,252 (1%) | 0% | 14.0 | 29,860 | Common Stock |
| James Patrick Mackin | President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 2,740 | 502,944 (1%) | 0% | 14.0 | 38,250 | Common Stock |
| James Patrick Mackin | President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 8,553 | 494,391 (1%) | 0% | 14.0 | 119,400 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 1,429 | 122,898 (0%) | 0% | 14.0 | 19,949 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 556 | 124,327 (0%) | 0% | 14.0 | 7,762 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 1,359 | 121,539 (0%) | 0% | 14.0 | 18,972 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 341 | 121,198 (0%) | 0% | 14.0 | 4,760 | Common Stock |
| John E. Davis | Senior VP, Global Sales | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 390 | 117,184 (0%) | 0% | 14.0 | 5,444 | Common Stock |
| John E. Davis | Senior VP, Global Sales | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 1,857 | 117,574 (0%) | 0% | 14.0 | 25,924 | Common Stock |
| John E. Davis | Senior VP, Global Sales | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 586 | 119,431 (0%) | 0% | 14.0 | 8,181 | Common Stock |
| Dennis B Maier | SVP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 380 | 42,085 (0%) | 0% | 14.0 | 5,305 | Common Stock |
| Dennis B Maier | SVP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 282 | 40,678 (0%) | 0% | 14.0 | 3,937 | Common Stock |
| Dennis B Maier | SVP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 1,125 | 40,960 (0%) | 0% | 14.0 | 15,705 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 1,125 | 30,414 (0%) | 0% | 14.0 | 15,705 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 282 | 30,132 (0%) | 0% | 14.0 | 3,937 | Common Stock |
| Matthew A. Getz | VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 363 | 31,539 (0%) | 0% | 14.0 | 5,067 | Common Stock |
| Rochelle L. Maney | VP, Quality | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.96 per share. | 17 Feb 2023 | 403 | 23,539 (0%) | 0% | 14.0 | 5,626 | Common Stock |
| David Ashley Lee | Executive VP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 36,822 | 0 | - | - | Stock Options (Right to buy) | |
| David Ashley Lee | Executive VP, COO & CFO | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 14 Feb 2023 | 31,900 | 335,563 (0%) | 0% | 13.2 | 421,874 | Common Stock |
| David Ashley Lee | Executive VP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.24 per share. | 14 Feb 2023 | 36,822 | 367,463 (0%) | 0% | 10.2 | 377,057 | Common Stock |
| James Patrick Mackin | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 65,549 | 0 | - | - | Stock Options (Right to buy) | |
| James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 14 Feb 2023 | 56,500 | 505,684 (1%) | 0% | 13.2 | 747,207 | Common Stock |
| James Patrick Mackin | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.24 per share. | 14 Feb 2023 | 65,549 | 562,184 (1%) | 0% | 10.2 | 671,222 | Common Stock |
| John E. Davis | Senior VP, Global Sales | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.24 per share. | 13 Feb 2023 | 8,745 | 120,017 (0%) | 0% | 10.2 | 89,549 | Common Stock |
| John E. Davis | Senior VP, Global Sales | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2023 | 8,745 | 0 | - | - | Stock Options (Right to buy) | |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 10.30 per share. | 31 Dec 2022 | 384 | 124,883 (0%) | 0% | 10.3 | 3,956 | Common Stock |
| Jean F. Holloway | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 16.05 per share. | 31 Dec 2022 | 866 | 124,499 (0%) | 0% | 16.0 | 13,898 | Common Stock |
| John E. Davis | Senior VP, Global Sales | Grant, award, or other acquisition of securities at price $ 16.05 per share. | 31 Dec 2022 | 1,228 | 111,272 (0%) | 0% | 16.0 | 19,707 | Common Stock |
| Dennis B Maier | SVP, Operations | Grant, award, or other acquisition of securities at price $ 16.05 per share. | 31 Dec 2022 | 211 | 42,465 (0%) | 0% | 16.0 | 3,386 | Common Stock |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 31 Dec 2022 | 443 | 40,448 (0%) | 0% | 10.3 | 4,564 | Common Stock | |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 31 Dec 2022 | 810 | 40,005 (0%) | 0% | 16.0 | 12,999 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Gift of securities by or to the insider at price $ 13.21 per share. | 14 Dec 2022 | 2,000 | 99,950 (0%) | 0% | 13.2 | 26,420 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 13.57 per share. | 14 Dec 2022 | 3,226 | 101,950 (0%) | 0% | 13.6 | 43,783 | Common Stock |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 11,831 | 105,176 (0%) | 0% | 0 | Common Stock | |
| Amy D. Horton | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 28,370 | 28,370 | - | - | Common Stock | |
| David Ashley Lee | Executive VP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 88,043 | 88,043 | - | - | Common Stock | |
| David Ashley Lee | Executive VP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 36,718 | 330,641 (0%) | 0% | 0 | Common Stock |